Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,834 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clinical Efficacy Clear all
Terminated Phase 1 Interventional

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

NCT03162562
View directory record Official record
Conditions
Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Stage IV, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovary Cancer
Interventions
Oregovomab, Poly ICLC
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 21, 2026, 5:59 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 21, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

Cefixime Clinical Trial

NCT04958122
View directory record Official record
Conditions
Syphilis, Human Immunodeficiency Virus
Interventions
Cefixime 400mg, benzathine penicillin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Compare the Clinical Efficacy of Prototype Toothpastes.

NCT00761930
View directory record Official record
Conditions
Gingival Diseases
Interventions
Fluoride, Triclosan and fluoride, Herbal Ingredient and fluoride
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 21, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

NCT07705607
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Orlando, Florida • Winter Haven, Florida • Hagerstown, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

NCT04980495
View directory record Official record
Conditions
Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

NCT05765175
View directory record Official record
Conditions
Tachycardia, Ventricular
Interventions
Varian Cardiac Radioablation (CRA), Catheter Ablation (CA)
Device · Procedure
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Hartford, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 21, 2026, 5:59 AM EDT
Not listed Phase 4 Interventional

ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study

NCT01881711
View directory record Official record
Conditions
Suspected CSF Shunt Obstruction
Interventions
ShuntCheck-Micro-Pumper (SCMP), Imaging
Device
Lead sponsor
NeuroDx Development
Industry
Eligibility
35 Months to 29 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 21, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial

NCT00546429
View directory record Official record
Conditions
Femoral Fracture (Proximal)
Interventions
Intramedullary nailing
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Colorado Springs, Colorado • Englewood, Colorado • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

NCT03326102
View directory record Official record
Conditions
Recurrent or Metastatic Breast Cancer
Interventions
DHP107, IV Paclitaxel
Drug
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers

NCT06557122
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SOC and Advanced Bioengineered Skin Substitute, SOC and Active Comparator
Device · Other
Lead sponsor
Encoll Corp
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • South Miami, Florida • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 21, 2026, 5:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Prospective, Single Center, Single-Arm Clinical Study of 20 Participants to Reduce the Appearance of the Peri-orbital Wrinkles. Participants Will Receive up to Four Treatments With Tixel Every 4 Weeks. Follow-up Will Occur 1 Month and 3 Months Following Last Treatment.

NCT05282979
View directory record Official record
Conditions
Wrinkle
Interventions
Tixel 2
Device
Lead sponsor
Physicians Laser and Dermatology Institute
Other
Eligibility
35 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 21, 2026, 5:59 AM EDT
Completed No phase listed Observational

Pediatric Locking Nail for the Treatment of Femoral Fractures in Children

NCT00725894
View directory record Official record
Conditions
Femur Fracture
Interventions
Pediatric Locking Nail
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
8 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Orlando, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 21, 2026, 5:59 AM EDT
Not listed Phase 4 Interventional

Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia

NCT02999737
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Platelet Rich Plasma for 4 sessions, Platelet rich plasma for 2 sessions
Biological
Lead sponsor
Skin Care and Laser Physicians of Beverly Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

NCT01922037
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
145
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

NCT01539239
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Aqueous Implant, Cataract surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 21, 2026, 5:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

NCT04404595
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer
Interventions
CT041
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 76 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 21, 2026, 5:59 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

NCT00330265
View directory record Official record
Conditions
Foot Ulcer, Diabetes
Interventions
KC-002, Conventional Wound Therapy
Device · Other
Lead sponsor
KeraCure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma

NCT01689662
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

NCT03005145
View directory record Official record
Conditions
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
Interventions
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Other
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
3,622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 21, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901
View directory record Official record
Conditions
Obese But Otherwise Healthy Participants
Interventions
CRB-913, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 5:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

NCT04228666
View directory record Official record
Conditions
Alzheimer Disease
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 21, 2026, 5:59 AM EDT